Skip to main content

Advertisement

SpringerLink
Log in

Programmatic Effectiveness of Latent Tuberculosis Care Cascade in a Community Health Center

  • Original Paper
  • Published:
Journal of Immigrant and Minority Health Aims and scope Submit manuscript

Abstract

Our aim was to quantify successful completion of steps of the latent tuberculosis (LTBI) care cascade in a community health center (CHC) with a large foreign-born population. We conducted a retrospective cohort study of individuals with a positive test for tuberculosis (TB) infection from 2015 to 2017 at Baltimore Medical Systems (BMS). During the study period, 3,984 individuals were tested for TB. Of the 418 individuals with positive tests, 152 (36%) were referred elsewhere for care, whereas 266 (64%) were retained in care at BMS. Treatment was prescribed for 157 of the 214 (73%) diagnosed with LTBI and retained in care at BMS (125/157 [80%] four months of rifampin; 32/157 [20%] nine months of isoniazid). One hundred forty-one patients (141/157, 90%) initiated treatment, of which 119 completed therapy (119/141, 84%). Our study identified several gaps in the LTBI care cascade in a CHC. Nonetheless, a large proportion of those treated for LTBI at the CHC completed therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. World Health Organization Global Tuberculosis Report 2018. World Health Organization, 2018.

  2. Latent tuberculosis infection: Updated and consolidated guidelines for programmatic management. World Health Organization, 2018.

  3. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent mycobacterium tuberculosis infection. The New England Journal of Medicine. 2015;372(22):2127.

    Article  CAS  Google Scholar 

  4. Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: A systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269–78.

    Article  Google Scholar 

  5. Rangaka MX, Cavalcante SC, Marais BJ. Controlling the seedbeds of tuberculosis: Diagnosis and treatment of tuberculosis infection. The Lancet. 2015;386(10010):2344–53.

    Article  Google Scholar 

  6. Miramontes R, Hill AN, Yelk-Woodruff RS. Tuberculosis infection in the united states: prevalence estimates from the national health and nutrition examination survey, 2011–2012. PLoS ONE. 2015;10(11):e0140881.

    Article  Google Scholar 

  7. Mancuso JD, Diffenderfer JM, Ghassemieh BJ, Horne DJ, Kao T. The prevalence of latent tuberculosis infection in the united states. Am J Respir Crit Care Med. 2016;194(4):501–9.

    Article  CAS  Google Scholar 

  8. Schmit KM, Wansaula Z, Pratt R, et al. Tuberculosis — united states, 2016. Morb Mortal Wkly Rep. 2017;66(11):289–94.

    Article  Google Scholar 

  9. Tsang CA, Langer AJ, Navin TR, Armstrong LR. Tuberculosis among foreign-born persons diagnosed ≥10 years after arrival in the united states, 2010–2015. Am J Transplant. 2017;17(5):1414–7.

    Article  Google Scholar 

  10. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for latent tuberculosis infection in adults: US preventive services task force recommendation statement. JAMA. 2016;316(9):962–9.

    Article  Google Scholar 

  11. Centers for Disease Control and Prevention. Tuberculosis panel physicians technical instructions. https://www.cdc.gov/immigrantrefugeehealth/exams/ti/panel/tuberculosis-panel-technical-instructions.html. Updated 2018. Accessed Apr 13, 2019.

  12. Keen E, Palmer A, Paulos L, Baruch N, Cronin W. “Program evaluation of tuberculosis B-waiver arrival epidemiologic data in Maryland, 2008–2012.” National TB Controllers Association 2015 National Conference Poster Exhibition.

  13. Desale M, Bringardner P, Fitzgerald S, Page K, Shah M. Intensified case-finding for latent tuberculosis infection among the baltimore city hispanic population. J Immigrant Minority Health. 2013;15(4):680–5.

    Article  Google Scholar 

  14. Nuzzo J, Golub J, Chaulk P, Shah M. Analysis of latent tuberculosis infection treatment adherence among refugees and other patient groups referred to the baltimore city health department TB clinic, february 2009–March 2011. J Immigrant Minority Health. 2015;17(1):56–655.

    Article  Google Scholar 

  15. Nuzzo JB, Golub JE, Chaulk P, Shah M. Postarrival tuberculosis screening of high-risk immigrants at a local health department. Am J Public Health. 2015;105(7):1432–8.

    Article  Google Scholar 

  16. Subedi P, Drezner KA, Dogbey MC, Newbern EC, Yun K, Scott KC, Garland JM, Altshuler MJ, Johnson CC. Evaluation of latent tuberculous infection and treatment completion for refugees in Philadelphia, PA, 2010–2012. Int J Tuberc Lung Dis. 2015;19(5):565–9.

    Article  CAS  Google Scholar 

  17. Centers for Disease Control and Prevention. Treatment regimens for latent TB infection (LTBI). https://www.cdc.gov/tb/topic/treatment/ltbi.htm. Updated 2016. Accessed April 13, 2019.

  18. Page KR, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: A retrospective study. Arch Intern Med. 2006;166(17):1863–70.

    Article  CAS  Google Scholar 

  19. Moro RN, Borisov AS, Saukkonen J, Khan A, Sterling TR, Villarino ME, Scott NA, Shang N, Kerrigan A, Goldberg SV. Factors associated with noncompletion of latent tuberculosis infection treatment: experience from the PREVENT TB trial in the United States and Canada. Clin Infect Dis. 2016;62(11):1390–400.

    Article  CAS  Google Scholar 

  20. Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Benedetti A. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. The New England Journal of Medicine. 2018;379(5):440–53.

    Article  CAS  Google Scholar 

  21. Hirsch-Moverman Y, Shrestha-Kuwahara R, Bethel J, et al. Latent tuberculous infection in the united states and canada: Who completes treatment and why? Int J Tuberc Lung Dis. 2015;19(1):31–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Washington University School of Medicine, Department of Medicine, Division of General Medicine, St. Louis, MO, USA

    Christopher Prater

  2. Johns Hopkins University School of Medicine, Department of Medicine, Division of Infectious Disease, Baltimore, MD, USA

    Samuel Holzman & Maunank Shah

  3. Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

    Samuel Holzman

Authors
  1. Christopher Prater
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samuel Holzman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maunank Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher Prater.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prater, C., Holzman, S. & Shah, M. Programmatic Effectiveness of Latent Tuberculosis Care Cascade in a Community Health Center. J Immigrant Minority Health 23, 566–573 (2021). https://doi.org/10.1007/s10903-020-01047-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10903-020-01047-w

Keywords

Search

Navigation